問卷

TPIDB > Search Result

Search Result

篩選

List

5Cases

2025-09-15 - 2030-12-31

Phase III

Active
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF TRONTINEMAB IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE TO AD)
  • Condition/Disease

    EARLY SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE TO AD)

  • Test Drug

    injection

Participate Sites
8Sites

Recruiting8Sites

2025-04-15 - 2032-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-05-20 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-07-22 - 2025-11-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-07-22 - 2025-11-30

Phase III

An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    Enfortumab vedotin

Participate Sites
7Sites

Recruiting7Sites